Opening Asia for Russia

Japan approves another anti-covid drug

28.09.2021 121 просмотров

The Japanese Ministry of Health, Labor and Welfare has approved another drug for the treatment of mild forms of the coronavirus disease. This is the second drug that has been given the green light in the country following the antibody cocktail.

On Monday, the ministry approved sotrovimab, manufactured by British pharmaceutical giant GlaxoSmithKline.

On the same day, the ministry's panel of experts assessed and recognized the drug's efficacy and safety.

Sotrovimab is a neutralizing antibody which weakens the coronavirus. The drug is administered intravenously.

This medicine is necessary for patients with mild to moderate symptoms who do not require oxygen, but who are at high risk of developing a severe form of the disease.

Clinical trials conducted abroad have shown that the drug reduces the risk of hospitalization or death by 79%. In May, the drug was approved for emergency use by the US Food and Drug Administration.

Новости партнёров